Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of modRNA Influenza Vaccine in Healthy Individuals
NCT05052697Phase 2Completed
- Sponsor
- Pfizer
- Start
- Sep 2021
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of camizestrant in influenza, sponsored by Pfizer. Started Sep 2021; status: completed.
02
Drugs
camizestrant
03
Conditions
influenza
Beyond the preview
Go deeper on NCT05052697.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05052697.